Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

The trials aim to evaluate MariTide's potential as a monthly alternative to weekly obesity treatments from Novo Nordisk and Eli Lilly.

Amgen has initiated two late-stage clinical trials for its experimental weight-loss drug, MariTide, involving approximately 4,500 participants.
The trials will assess the percentage of weight loss over 72 weeks in obese or overweight individuals, with one study focusing on patients with Type 2 diabetes.
MariTide is designed as a monthly injectable, positioning it as a potential competitor to weekly treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
In earlier Phase 2 trials, MariTide showed an average weight loss of up to 20% over a year, though results fell short of some investor expectations.
The studies will explore multiple dosing levels, with results expected to provide further insights into the drug's efficacy and market potential.